CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
VM202-0.5 mg +2 morebiological
Likely dose
VM202-0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01422772
NCT01422772Phase 2Completed
CompareCT.gov

Open-label, Non-comparative, Dose-escalation, Single-center, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Cardiac Muscle of Incompletely Revascularized Area After CABG in Patients With Ischemic Heart Diseases

Helixmith Co., Ltd.·interventional·Posted Aug 24, 2011·Updated Oct 3, 2025

In Brief

A Phase 2 clinical trial evaluating VM202-0.5 mg, VM202-1.0 mg, and 1 other intervention for Ischemic Heart Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety of VM202 (Engensis) direct injection into the cardiac muscles of the coronary artery territory where complete revascularization could not be done even through Coronary Artery Bypass Graft (CABG).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Heart Disease
CountriesSouth Korea
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2011
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.9 years ago

Interventions

VM202-0.5 mgbiological

0.5 mg intramyocardial injection

VM202-1.0 mgbiological

1 mg intramyocardial injection

VM202-2.0 mgbiological

2 mg intramyocardial injection